What the changes say
- Drug-pricing pressure now includes the 2025 Part D redesign, Medicaid reductions, possible tariffs, and most-favored-nation pricing demands.
- Competition is more concrete: Winrevair and Yutrepia are launched competitors, while Insmed’s TPIP and new IPF therapies are advancing.
- The filing adds explicit concern about patent defenses, trade-secret protection, and unauthorized use of proprietary technology.
What changed since the prior 10-K
New
- NewRisks Related to Legal Compliance
Tyvaso DPI and Orenitram revenues could be offset because the IRA’s Part D redesign, which went into effect in 2025 and resulted in an increase in the number of patients able to afford these therapies. The amount of the offset, if any, is inherently uncertain and difficult to predict
Part D redesign, Medicaid cuts, potential pharmaceutical tariffs, and most-favored-nation pricing could reduce Tyvaso DPI and Orenitram sales or pricing.
- NewRisks Related to Our Intellectual Property and Data Privacy
Patent litigation can be time consuming, distracting, and costly, and the outcome may be difficult to predict and unfavorable to us. If we are unsuccessful in the defense of our patents, our business could be negatively impacted
Patent disputes and loss or unauthorized disclosure of trade secrets could weaken United Therapeutics’ competitive position and product protection.
Dropped
- DroppedRisks Related to Our Products and Our Operations
significant number of additional therapies being developed for the treatment of IPF, which would compete with Tyvaso DPI and nebulized Tyvaso if either of them is ultimately approved for that indication
- DroppedRisks Related to Legal Compliance
It is difficult to predict the impact, if any, that future legislation or executive actions might have on the use of and reimbursement for our products in the United States, including the potential for the importation of generic versions of our products
- DroppedRisks Related to Legal Compliance
contract pharmacy policy. In November 2021, the court granted our motion for summary judgment, ruling that the letters threatening enforcement action “contain legal reasoning that rests upon an erroneous reading of Section 340B.” HRSA appealed, and the appellate court affirmed the lower court’s decision in our favor
- DroppedRisks Related to Legal Compliance
fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions, or incur other harm to our business
Competition from additional IPF therapies against Tyvaso DPI and nebulized Tyvaso.
- DroppedRisks Related to Our Intellectual Property and Data Privacy
Third parties may allege that our products or services infringe their patents and other intellectual property rights, which could result in the payment of royalties that negatively affect our profits, subject us to costly and time-consuming litigation, or cause us to lose the ability to sell the related products
- DroppedRisks Related to Our Financing Capacity, Indebtedness, and Investments
We may not be able to generate sufficient cash to service or repay our indebtedness, which may have a material adverse effect on our financial position, results of operations, and cash flows
Reworded
- 100% rewrittenRisks Related to Our Products and Our Operations
United Therapeutics, a public benefit corporation
The focus shifts from Tyvaso DPI manufacturing capacity to named competition from Winrevair, Yutrepia, TPIP, and new IPF therapies.
- 81% rewrittenRisks Related to Our Products and Our Operations
Our manufacturing strategy exposes us to significant risks
No substantive change; the text is materially identical apart from capitalization of “Nebulized Tyvaso.”
- 71% rewrittenRisks Related to Legal Compliance
We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program
No substantive change in the provided body; it continues describing the company’s 340B contract-pharmacy policy.
- 57% rewrittenRisks Related to Legal Compliance
Government healthcare reform and other reforms could adversely affect our revenue, costs, and results of operations
The risk now says even unlawful or repealed healthcare proposals or executive actions could still damage the pharmaceutical sector and company.
- 53% rewrittenRisks Related to Legal Compliance
The increasing use of social media platforms and artificial intelligence-based software presents new risks and challenges
The heading adds artificial-intelligence risks, but the provided body remains focused on social-media communications and adverse-event reporting.
- 47% rewrittenRisks Related to Legal Compliance
We must comply with extensive laws and regulations in the United States and other countries. Failure to obtain approvals on a timely basis or to comply with these requirements could delay, disrupt, or prevent commercialization of our products
The regulatory discussion shifts from transplantation programs to the organ manufacturing program and adds post-approval manufacturing, distribution, labeling, and reporting obligations.
- 42% rewrittenRisks Related to Our Products and Our Operations
We may not compete successfully with established or newly developed drugs or products
No substantive change; the competition discussion and example of more than fifteen branded and generic PAH drugs remain the same.
- 32% rewrittenRisks Related to Our Intellectual Property and Data Privacy
Our intellectual property rights may not effectively deter competitors from developing competing products that, if successful, could have a material adverse effect on our revenues and profits
No substantive change; the text is materially identical apart from capitalization of “Nebulized Tyvaso.”
- 25% rewrittenRisks Related to Our Products and Our Operations
We rely in part on third parties to perform activities that are critical to our business
- 23% rewrittenRisks Related to Our Products and Our Operations
Negative attention from special interest groups may impair our business
All 32 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Products and Our Operations
- 01We rely heavily on sales of our treprostinil-based therapies to generate revenues and support our operations
- 02If our products fail in clinical trials, we will be unable to sell those products
- 03We may not compete successfully with established or newly developed drugs or products42% rewritten
- 04United Therapeutics, a public benefit corporation100% rewritten
- 05The successful commercialization of our products depends on the availability of coverage and adequacy of reimbursement from third-party payers, including governmental authorities and private health insurers. Pharmaceutical pricing and reimbursement pressures may negatively impact our sales
- 06Our manufacturing strategy exposes us to significant risks81% rewritten
- 07We rely in part on third parties to perform activities that are critical to our business25% rewritten
- 08Reports of actual or perceived side effects and other adverse effects associated with our products could cause our sales to decrease or regulatory approvals to be revoked
- 09Negative attention from special interest groups may impair our business23% rewritten
- 10We may not maintain adequate insurance coverage to protect us against significant product liability claims
- 11If we fail to attract and retain key management and qualified scientific and technical personnel, we may not be able to achieve our business objectives
Risks Related to Legal Compliance
- 12We must comply with extensive laws and regulations in the United States and other countries. Failure to obtain approvals on a timely basis or to comply with these requirements could delay, disrupt, or prevent commercialization of our products47% rewritten
- 13Regulatory approval for our currently marketed products is limited by the FDA and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated
- 14We must comply with various laws in jurisdictions around the world that restrict certain marketing practices
- 15Government healthcare reform and other reforms could adversely affect our revenue, costs, and results of operations57% rewritten
- 16Tyvaso DPI and Orenitram revenues could be offset because the IRA’s Part D redesign, which went into effect in 2025 and resulted in an increase in the number of patients able to afford these therapies. The amount of the offset, if any, is inherently uncertain and difficult to predictnew
- 17We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program71% rewritten
- 18Improper handling of hazardous materials used in our activities could expose us to significant remediation liabilities
- 19The increasing use of social media platforms and artificial intelligence-based software presents new risks and challenges53% rewritten
Risks Related to Our Intellectual Property and Data Privacy
- 20If any of the agreements under which we license or acquired intellectual property rights are breached or terminated, we could lose our rights to continue to develop, manufacture, and sell the products covered by such agreements
- 21Our intellectual property rights may not effectively deter competitors from developing competing products that, if successful, could have a material adverse effect on our revenues and profits32% rewritten
- 22Patent litigation can be time consuming, distracting, and costly, and the outcome may be difficult to predict and unfavorable to us. If we are unsuccessful in the defense of our patents, our business could be negatively impactednew
- 23Cybersecurity incidents and other disruptions impacting our networks, systems, or data may have a material adverse effect on our business
Risks Related to Our Financing Capacity, Indebtedness, and Investments
- 24If we need additional financing and cannot obtain it, our product development and sales efforts may be limited
- 25Our portfolio of investments is subject to market, interest, operational, and credit risk that may reduce its value
- 26If we are not able to successfully identify, finance, consummate, and/or integrate acquisitions, our business operations and financial position could be adversely affected
Risks Related to Our Common Stock
- 27The price of our common stock can be highly volatile and may decline
- 28Provisions of Delaware law, our charter, bylaws and employment and license agreements, among other things, could prevent or delay a change of control or change in management that may be beneficial to our public shareholders
- 29Our shareholders must rely on stock appreciation for any return on their investment in us
- 30Our exclusive forum bylaw may limit our shareholders’ ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers, or other employees
- 31We may not be able to achieve our public benefit purpose or realize the expected positive impacts from being a PBC
- 32As a Delaware PBC, we may be subject to increased litigation risk
Other UNITED Therapeutics 10-Ks
- 2025 10-K risk factors
36 risks. Treprostinil therapies generate most revenue, making product sales, competition, reimbursement, and manufacturing central risks.
Filed Feb 26, 2025
About this page
Item 1A of the 10-K on EDGAR was split into its risk factors and, where the company's previous 10-K is on file, each heading was matched to last year's and the text compared word for word. The headings are the filing's own. The one-line readings and the overview were written by a language model from the text of the new, dropped, and rewritten risks; they refer to risks by position and cannot misquote a heading.